Last reviewed · How we verify

Brepocitinib PO QD — Competitive Intelligence Brief

Brepocitinib PO QD (Brepocitinib PO QD) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK1/TYK2 inhibitor. Area: Immunology.

phase 3 JAK1/TYK2 inhibitor JAK1, TYK2 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Brepocitinib PO QD (Brepocitinib PO QD) — Priovant Therapeutics, Inc.. Brepocitinib is a dual JAK1/TYK2 inhibitor that suppresses inflammatory signaling pathways to reduce immune-mediated tissue damage.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Brepocitinib PO QD TARGET Brepocitinib PO QD Priovant Therapeutics, Inc. phase 3 JAK1/TYK2 inhibitor JAK1, TYK2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK1/TYK2 inhibitor class)

  1. Priovant Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brepocitinib PO QD — Competitive Intelligence Brief. https://druglandscape.com/ci/brepocitinib-po-qd. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: